氟维司群治疗激素受体阳性晚期乳腺癌的疗效和安全性分析

Efficacy and safety of fulvestrant for treating patients with hormone receptor positive advanced breast cancer

摘要:

目的：探讨氟维司群治疗激素受体（hormone receptor，HR）阳性晚期乳腺癌患者的临床疗效和安全性。方法：收集2015年1月至2019年6月就诊于广西医科大学附属肿瘤医院的80例经氟维司群治疗的HR阳性晚期乳腺癌患者临床资料，并对氟维司群的临床疗效、影响因素和不良反应进行回顾性分析。结果：中位随访时间为6.7（2.0，35.6）个月，中位治疗周期为7（2，28）个周期，患者的无进展生存时间（progression-free survival，PFS）为9.3个月（95%CI=4.64～13.96）；客观缓解率（objective response rate，ORR）为2.5%，临床获益率（clinical benefit rate，CBR）为40.0%。COX多因素分析显示，患者的PFS与既往接受姑息化疗的线数有关[HR=2.18（1.55，3.08），P=0.000]。本组患者使用氟维司群后整体安全性良好，未出现Ⅲ级及以上不良反应，且未发生治疗相关性死亡。结论：500 mg 氟维司群治疗激素受体阳性晚期乳腺癌患者的临床疗效显著，安全性良好。

Abstract:

Objective：To investigate the efficacy and safety of fulvestrant for treating patients with hormone receptor（HR） positive advanced breast cancer. Methods：Clinical data of 80 patients with HR positive advanced breast cancer who were treated with fulves－trant in our hospital from January 2015 to June 2016 were collected. The clinical efficacy of fulvestrant，influencing factors and ad－verse effect were evaluated. Results：The median follow-up was 6.7 months（2.0，35.6 months），median treatment cycle was 7 cycles （2，28 cycles），median progression free survival（PFS） was 9.3 months（95%CI=4.64-13.96），objective response rate（ORR） was 2.5% and clinical benefit rate（CBR） was 40.0%. COX multivariate analysis indicated that PFS was correlated with previous lines of chem-otherapy[HR=2.18（1.55，3.08），P=0.000]. Conclusion：Fulvestrant of 500 mg has a favorable efficacy in patients with HR positive advanced breast cancer，with good safety.